SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-14 |
| Reported value | $2,212,480,490 |
| Positions | 113 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ROIVANT SCIENCES LTD | ROIV | SHS | $132,712,500 | 3,750,000 |
| APOGEE THERAPEUTICS INC | APGE | COM | $131,004,510 | 987,000 |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $113,561,517 | 1,279,134 |
| XENON PHARMACEUTICALS INC | XENE | COM | $96,274,200 | 1,595,000 |
| ERASCA INC | ERAS | COM | $96,180,000 | 5,250,000 |
| INSMED INC | INSM | COM PAR $.01 | $69,303,000 | 650,000 |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $61,936,150 | 185,000 |
| ALKERMES PLC | ALKS | SHS | $58,944,375 | 1,125,000 |
| ORUKA THERAPEUTICS INC | ORKA | COM | $56,150,300 | 590,000 |
| ANAPTYSBIO INC | ANAB | COM | $55,762,358 | 826,109 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.